Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions
SARS-CoV-2, the causative agent of COVID-19, has caused more than 60 million cases worldwide with almost 1.5 million deaths as of November 2020. Repurposing existing drugs is the most rapid path to clinical intervention for emerging diseases.
Enregistré dans:
Auteurs principaux: | Christopher J. Day, Benjamin Bailly, Patrice Guillon, Larissa Dirr, Freda E.-C. Jen, Belinda L. Spillings, Johnson Mak, Mark von Itzstein, Thomas Haselhorst, Michael P. Jennings |
---|---|
Format: | article |
Langue: | EN |
Publié: |
American Society for Microbiology
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2b06afb56d02402cb0d88feb912f1af0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The glycosylation in SARS-CoV-2 and its receptor ACE2
par: Yanqiu Gong, et autres
Publié: (2021) -
The molecular basis for SARS-CoV-2 binding to dog ACE2
par: Zengyuan Zhang, et autres
Publié: (2021) -
Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
par: Jinsung Yang, et autres
Publié: (2020) -
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
par: Kushal Suryamohan, et autres
Publié: (2021) -
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
par: Jiwan Ge, et autres
Publié: (2021)